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Summary
Human UDP-glucuronosyltransferases (UGT) are the dominant phase II conjugative drug
metabolism enzymes that also play a central role in the processing of a range of endobiotic
compounds. UGTs catalyze the covalent addition of glucuronic acid sugar moieties to a host of
therapeutics and environmental toxins, as well as to a variety of endogenous steroids and other
signaling molecules. We report the 1.8 Å resolution apo crystal structure of the UDP-glucuronic acid
binding domain of human UGT isoform 2B7 (UGT2B7), which catalyzes the conjugative elimination
of opioid, antiviral, and anticancer drugs. This is the first crystal structure of any region of a
mammalian UGT drug metabolism enzyme. Designed UGT2B7 mutants at residues predicted to
interact with the UDP-glucuronic acid cofactor exhibited significantly impaired catalytic activity,
with maximum effects observed for amino acids closest to the glucuronic acid sugar transferred to
the acceptor molecule. Homology modeling of UGT2B7 with related plant flavonoid
glucosyltransferases indicate that human UGTs share a common catalytic mechanism. Point
mutations at predicted catalytic residues in UGT2B7 abrogated activity, strongly suggesting that
human UGTs also utilize a serine hydrolase-like catalytic mechanism to facilitate glucuronic acid
transfer.
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UDP-glucuronosyltransferases (EC 2.4.1.17; UGTs) are major vertebrate phase II conjugative
metabolism enzymes that process and/or detoxify a large number of important endogenous
compounds, drugs, and environmental agents (reviewed here 1,2). UGTs are highly
promiscuous, catalyzing the covalent addition of a glucuronic acid moiety from the UDP-
glucuronic acid (UDPGA) donor ligand to chemically distinct functional groups present on a
range of structurally diverse acceptor substrates. This reaction frequently results in a
biologically inactive, water soluble glucuronide that is rapidly excreted. Thus, these enzymes
play central roles in endobiotic homeostasis and metabolic defense systems.
The UGT superfamily of enzymes in humans consists of 18 members that can be further divided
by sequence homology into two main subfamilies: UGT1A and UGT2. The UGT1A family
includes nine members (1A1, 1A3, 1A4, 1A5, 1A6, 1A7, 1A8, 1A9, and 1A10) that share a
common genetic structure – each is composed of a unique exon 1 spliced to a common set of
exons 2-5. While the UGT2 family also includes nine members (2A1, 2A2, 2B4, 2B7, 2B10,
2B11, 2B15, 2B17, and 2B28), each isoform exhibits a unique genetic structure. UGTs are
type 1 transmembrane glycoproteins of approximately 530 amino acids localized
predominantly to the endoplasmic reticulum (ER) and nuclear membranes3. The majority of
the protein is in the ER lumen and is composed of two functional domains, N-terminal and C-
terminal, thought to contain the acceptor substrate and UDPGA binding sites, respectively. In
addition, the N-terminal domain is thought to contain a cryptic ER retention signal as well as
a membrane interacting region 4,5. Human UGTs have also been shown to from both homo-
and heterodimers, which may have an effect on function and acceptor ligand specificity 6,7,
8,9.
UGTs have highly similar C-terminal domains and highly variable N-terminal domains,
thereby imparting to each enzyme a distinct, but often overlapping set of substrate specificities.
In particular, all UGT1A proteins, due to common exons 2-5, share an identical C-terminal
domain. UGTs are most abundantly expressed in the liver but are also present in variety of
other tissues, including the GI tract, kidney, and lung. Thus, UGTs are involved in the
metabolism of a wide range of injected, inhaled, and orally administered drugs and other
xenobiotics. UGTs are also present in steroid-sensitive tissues like the colon, mammary gland,
and prostate, where they regulate the levels of a host of important endobiotics including steroid
hormones, retinoids, and bile acids 10,11,12,13, providing protection against the generation
and/or progression of certain forms of cancer.
Glycosyltransferases (GTs) have been divided into 87 families (GTx) based on amino acid
similarities and the types of donor ligand utilized 14,15 (Carbohydrate-Active Enzymes server
at http://afmb.cnrsmrs.fr/CAZY/index.html). Structural examination of GTs has sometimes
been hampered by the difficulties associated with their overexpression, purification, and
crystallization. In particular, production of soluble, full length human UGT that generates
crystals has yet to be reported despite intense efforts by us and other research groups 4,5.
Currently, structural information is available for only a limited number of GT families,
revealing two distinct structural folds, GT-A and GT-B 16. GT-A proteins consist of a single
α/β/α sandwich that resembles a Rossman-like fold and contains a divalent metal that is
important for donor ligand binding. GT-B enzymes are composed of two Rossman-like
domains that associate to form a catalytic cleft at their interface. While there is cross talk
between the domains the majority of the donor ligand contacts are contributed by the C-terminal
domain while the majority of the acceptor substrate contacts are contributed by the N-terminal
domain. In contrast to GT-A fold-containing GTs, the activity of GT-B enzymes are not
dependent on divalent metals; however, these metals enhance the activity of some GT-B
enzymes 17,18.
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Human UGTs belong to the GT1 family 14,15 and are predicted to adopt a GT-B fold 16.
Crystal structures of several GT1 family members have been solved in recent years, including
the bacterial Gtf family of enzymes involved with vancomycin synthesis 19,20,21, and two
flavonoid GTs from plants 22,23, which are important for the glycosylation of secondary
metabolites. We determined the 1.8 Å resolution x-ray crystal structure of the C-terminal
domain of human UGT2B7, a major enzyme involved in the metabolism of important
endobiotic signaling molecules and therapeutics 24. UGT2B7 regulates the levels of many
potent endobiotic signaling molecules like androsterone, estriol, and retinoic acid. UGT2B7
also directly conjugates drugs from all major classes, including cancer therapeutics like
epirubicin and the AIDS drug AZT 25. In addition, UGT2B7 is the only human UGT able to
metabolize morphine-based opioids, which are central to the management of chronic and acute
pain. We present structural and functional data that elucidate numerous aspects of human UGT
donor-substrate binding and catalytic activity. Taken together, the results presented here
provide a foundation from which the molecular mechanisms behind human UGT donor-
substrate binding and catalytic activity can begin to be deciphered.
Results
Overall Structure
Significant efforts in our laboratory have been directed at producing soluble, human UGTs
suitable for crystallographic analyses. Despite employing multiple prokaryotic and eukaryotic
expression systems and a wide range of constructs, we have yet to be able to produce soluble
forms of a UGT containing both the N-terminal substrate and C-terminal cofactor binding
domains. Concurrent with these efforts, we also pursued separate N- and C-terminal domain
E. coli expression strategies for UGT2B7. The N-terminal domain proved to be highly unstable.
In contrast, the C-terminal domain (2B7CT, residues 285-451) was well behaved and
crystallized readily. The three dimensional structure was determined initially to 2.1 Å
resolution using multiwavelength anomalous dispersion (MAD) phasing and a single crystal
containing selenomethionine-substituted protein (Figure 1A). The resulting experimental
electron density map was of high quality for nearly all residues (Figure 1B). MAD methods
were utilized because molecular replacement with predicted structural homologs from
prokaryotic glycosyltransferases was not successful, and the structures of related
glucosyltransferases from plants were not yet available. The 2B7CT structure was ultimately
refined to 1.8 Å resolution using the low-remote wavelength data set collected from a different
region of the same crystal. Data collection, phasing, and refinement statistics are summarized
in Table 1.
The 2B7CT structure is a globular domain with a Rossman-type fold (Figure 1C). At the core
of the protein is a single parallel β-sheet consisting of six individual strands surrounded by
seven α-helices. This structure is consistent with the predictions from sequence similarities and
fold prediction algorithms like Phyre 26 that human UGTs belong to the GT-B fold family of
glycosyltransferases. The asymmetric unit contains two 2B7CT molecules that pack together
to form an asymmetric dimer (Figure 1A). These molecules are nearly identical, with a root
mean square deviation (RMSD) of 0.38 and 1.38 Å for 157 Cα atoms (residues 285-310,
315-446) and all atoms, respectively. They do contain small regions of differences. Residues
282-284, which are residual expression vector residues, and 447-451 were not modeled in chain
A due to poor electron density. Similarly, residues 311-314 from chain B also had poor electron
density and were not modeled.
Comparisons to Glycosyltransferase Structures
Structures of GT-B fold-containing glycosyltransferases from several GT classes have been
determined in recent years 16. These include phage T4 DNA glucosyltransferase (GT63) 27,
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28, MurG (GT28) 29,30, which is involved in peptidoglycan formation, and the Gtf family of
enzymes (GT1) involved with vancomycin synthesis 19,20,21. Two very recent structures of
GT1 family plant flavonoid glucosyltransferases, VvGT1 and UGT71G1, have been completed
22,23. Superposition of the C-terminal domains of GtfA and VvGT1 with 2B7CT reveals a
high level of structural homology despite their low sequence identity (∼19%), with RMSDs
of 1.95 Å over 141 Cα atoms, and 1.77 Å over 147 Cα atoms for each, respectively (Figure 2).
A structure based-sequence alignment of representative GT1 family enzymes is shown in
Figure 3. Although the majority of secondary structure elements are similar, discrete
differences exist. All structures significantly differ in both length and secondary structure for
the amino acids connecting Cβ2 and Cβ3. In VvGT1, both a 3/10 helix and α-helix Cα2 are
present in this region, while in both 2B7CT and GtfA a shorter loop structure is observed
(Figure 3).
UDPGA Binding Site
A hallmark feature of GT-B fold-containing enzymes is the di-phosphate nucleotide sugar
binding site formed by the C-terminal domain. Structurally characterized GT-B superfamily
enzyme nucleotide-sugar binding sites utilize a common structural scaffold; however, the
nature of the specific interactions with the donor ligands are varied, even amongst enzymes in
the same GT family. Comparison of 2B7CT with other GT1 family enzyme structures from
bacteria and plants (GtfA and VvGT1) in complex with donor ligands suggests that human
UGT2B7 binds UDPGA with an analogous site (Figure 4A). The presumptive UDPGA binding
site of UGT2B7 is remarkably similar to the UDP-glucose binding site of VvGT1 (Figure 4B),
with only a handful of amino acid differences. Most notable among them are VvGT1 residues
Ser306 and Ser355, which make hydrogen bonds to the uracil base and α-phosphate moieties,
respectively. This α-phosphate hydrogen bonding interaction is also seen in other GT-B
superfamily enzymes. Equivalent positions in 2B7CT are Arg338 and Gly379, respectively,
highlighting key areas of difference that may have functional significance.
The Gtf family of enzymes in bacteria utilize a dTDP-sugar donor ligand, while plant and
human UGTs utilize a UDP-sugar donor ligand. Comparison of this site between GtfA and
UGT2B7 revealed several differences (Figure 4C). Ser295 in GtfA hydrogen bonds to the O2G
phosphate oxygen; in plants and humans this residue is a glycine, resulting in a different di-
phosphate conformation in VvGT1. The thymine moiety is not pinned in place with a Trp
residue via a ring-stacking interaction; instead, a salt bridge between Glu277 and Arg207 holds
the nucleotide in place. Additionally, the region adjacent to the thymine is more hydrophobic
(Leu280/Leu301), which is complemented by the deoxy nature of the ribose. The short loop in
2B7CT/VvGT1 that connects Cα5 and Cβ5 makes direct contacts with the glucose moiety in
VvGT1. This loop is both longer and in an extended conformation in the GtfA structure, likely
due to only having a dTDP bound. The long length of this loop is thought to help accommodate
the large size of Gtf family enzyme acceptor substrates 21. Residues analogous to those in
VvGT1 that interact with the glucose moiety are conserved in both human UGTs (Asp398,
Gln399) and Gtf family proteins (Figure 3).
All attempts to co-crystallize 2B7CT with UDPGA were unsuccessful. Addition of UDPGA
to our crystallization conditions resulted in a concentration dependent inhibition of crystal
formation. Similarly, UDPGA soaking experiments with 2B7CT crystals also failed. Once the
structure was determined, it was clear that this due in part to the nature of the crystal packing
interactions in the asymmetric 2B7CT dimer in the crystallographic asymmetric unit (Figure
1A). The C-terminus of one monomer packs into the predicted UDPGA binding site of the
other monomer (Figure 4D). Removal of the C-terminal residues, in an effort to remove this
occlusion, produced protein samples that were highly unstable and could not be crystallized.
The UDPGA binding site of one 2B7CT monomer in the asymmetric unit is un-obstructed,
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however. Analysis of difference Fourier electron density maps between 2B7CT data and data
from crystals obtained in the presence of 8-fold molar excess UDPGA did not show any
significant density at the free nucleotide-sugar binding site (data not shown). This is perhaps
not surprising since the UDPGA binding site is only a shallow surface site on 2B7CT in the
absence of the N-terminal domain.
Examining the sequence conservation amongst human UGTs at the predicted UDPGA binding
site revealed a high level of sequence identity (Figure 3). Mapping this conservation to the
molecular surface of 2B7CT reveals that the majority of the binding site residues are invariant
(Figure 5), suggesting that all human UGTs interact with UDPGA in an analogous way. The
conserved sequence patch beneath the uracil base corresponds to residue 357 (Ile/Val).
However, only the mainchain atoms of this residue are predicted to interact with the uracil
base; the side chain is directed away from the binding site. Despite the overall low sequence
identity between VvGT1 and 2B7CT (19%), many of the residues that contact UDPglucose in
VvGT1 are conserved in human UGTs (Figure 3, 4B). In addition, a high degree of structural
similarity exists between the C-terminal domain of VvGT1 and 2B7CT at the VvGT1
nucleotide-sugar binding site. Taken together, these data strongly suggest that human UGTs
bind nucleotide-sugars in a way that is very similar to plant glucosyltransferases. Utilizing this
information we modeled UDPGA into the predicted nucleotide-sugar binding site of 2B7CT
(Figure 5).
Mutational Analysis Confirms UDPGA Binding Site
In order to validate our 2B7CT-UDPGA model, a series of enzyme activity assays were
conducted with microsomal fractions containing full-length UGT2B7 expressed in HighFive
insect cells. Using the 2B7CT-UDPGA model as a guide, the binding site was broken down
into three groups: residues predicted to interact with the uracil base, the di-phosphate group,
or the glucuronic acid moiety. A panel of point mutants at these positions were generated and
their impact on enzyme activity assessed with three distinct substrates (Figure 6).
Most mutations of residues surrounding the uracil base moderately impaired enzyme activity,
while others had only minor effects (Figure 6A). Trp356 is predicted to ring-stack with the
uracil base (Figure 4B), which is a type of interaction seen in other GT-B superfamily enzymes
29,31. Mutation of this residue to an alanine or histidine (a smaller aromatic residue) and the
resulting attenuated activity demonstrates the importance of this interaction to UGT2B7
function. The foundation provided by Gln359 to the uracil base appears to be of equal
importance. Disruption of the predicted hydrogen bond between Glu382 and the ribose 2'-OH
via an alanine mutation also impairs function. Residue Ser308 forms part of the uracil binding
pocket but is not predicted to make any direct contacts with the uracil base. An alanine mutation
at this position has little or no effect on activity, indicating a minor role in enzyme activity.
Arg338 was mutated to serine, mimicking the nucleotide binding site found in other GT1 family
glycosyltransferases. Restoring this uracil base hydrogen bonding interaction did not result in
increased activity, rather it had little or no effect. Interestingly, several mutants (e.g., S308A,
R338S, W356H) exhibited stronger effects on glucuronic acid transfer to some substrates
(e.g., TCC, HDCA) relative to others (e.g., androsterone). This observation suggests that the
positioning of the UDPGA cofactor may have a significant effect on catalytic activity. Subtle
alterations in UDPGA binding appear to impact the association of acceptor molecules within
the N-terminal region of the enzyme.
Mutations at residues predicted to interact with the di-phosphate moiety of UDPGA had
significant effects on enzyme function (Figure 6B). His374, a residue conserved in other GT1
family enzymes, is positioned directly beneath the β-phosphate. Mutation of this residue to
alanine or introduction of a negative charge via a glutamic acid mutation virtually eliminated
activity. A key contact in the AU dimer of 2B7CT occurs at this site. The negatively charged
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C-terminal aspartic acid sidechain of one molecule packs where the di-phosphate moiety is
predicted to bind (Figure 4D). Taken together, these observations support the idea that
His374 is acting to help neutralize the negative charge on the β-phosphate. The N-terminal end
of helix Cα4 is predicted to interact with the α-phosphate via its positively charged dipole, a
contact common to many GT-B superfamily glycosyltransferases 18. Hydrogen bonding
interactions also appear to be important, as mutation of Asn378, predicted to interact with the
α-phosphate, to an alanine results in a significant loss of activity.
Due to the presence of a glycine at position 379, a pocket is formed underneath the α-phosphate
in 2B7CT. This represents a major point of difference between human and other GT-B
superfamily enzymes, in which a highly conserved serine/threonine hydrogen bonds with the
α-phosphate. At the base of the pocket in 2B7CT is Thr373, which could interact with the α-
phosphate via a water- or ion-mediated contact. Although no divalent metal dependence has
been observed for GT-B superfamily enzymes, they have been shown to enhance significantly
the activity of some GT-B enzymes. Activity experiments with UGT2B7 were carried out in
the presence of EDTA and no appreciable loss or gain in activity was observed (Figure 6C).
A network of waters, however, is present in this pocket in the 2B7CT structure. Mutation of
Thr373 to a nearly iso-structural valine, which removes the hydrogen bonding potential of the
side chain, severely disrupts enzyme activity (Figure 6B) suggesting that water-mediated
contacts to the cofactor di-phosphate group are critical to enzyme function. Replacement of
Gly379in UGT2B7 with a serine makes another hydrogen bonding partner for UDPGA
available and results in an increase of activity compared to wildtype, while an aspartic acid
mutation eliminates activity, perhaps by nullifying the positive Cα4 helix dipole and/or direct
charge repulsion with the UDPGA di-phosphate moiety.
Several residues that are predicted to hydrogen bond to the glucuronic acid moiety are
absolutely critical for UGT2B7 function (Figure 6D). Asp398 and Gln399, which are conserved
in other GT1 family glycosyltransferases, are predicted to interact with O3'/O4' and O2'/O3'
atoms of glucuronic acid, respectively. Mutation of either residue to an alanine results in loss
of enzyme activity. A more conservative mutation of Asp398 to an asparagine also results in a
complete loss of activity, suggesting that a negative charge, not just hydrogen bonding
potential, is important at this position. Similar mutations at this position in structurally defined
plant glucosyltransferases also resulted in a loss of function 22,23. These residues are likely
important in defining the sugar specificity of human UGT enzymes. In addition, Asn378, due
to its predicted proximity to the glucuronic acid COOH group, may also be involved with donor
sugar selectivity.
Taken together, our UGT2B7 structural and functional data demonstrate that mutations
predicted to disrupt interactions with either the di-phosphate or glucuronic acid moieties of
UGT2B7 tended to abolish activity, while predicted uracil base interacting residues only
moderately reduce activity. These observations argue that interactions closest to the phosphate-
sugar bond being broken are the most important to enzyme activity.
Insights into the Catalytic Mechanism of Human UGTs
Recently, two groups published crystal structures of plant glucosyltransferases, each proposing
similar catalytic mechanisms 22,23. The structure of full length VvGT1 in complex with both
a non-hydrolyzable form of UDP-glucose and the acceptor substrate quercetin is shown in
Figure 7A. Using this structure as a starting point, the software package loopp was used to
generate a homology model of UGT2B7 32. Inspection of this model at the catalytic center
revealed that UGT2B7 has residues analogous to plant glucosyltransferases at key catalytic
positions (His35, Asp151). This model predicts that human UGTs use a serine hydrolase-like
catalytic triad for catalysis. His35 of UGT2B7 deprotonates a suitable atom of the acceptor
ligand, facilitating a nucleophilic attack at the C1 atom of glucuronic acid (Figure 7B). The
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resulting protonated histidine is stabilized by a neighboring aspartic acid at position 151.
Mutation of His35 to alanine or Asp151 to either alanine or asparagine resulted in a catalytically
inactive enzyme (Figure 6E). Similar mutations in plant glucosyltransferases had equivalent
results 22,23, as did analogous mutations in the serine protease members of the serine hydrolase
superfamily 33. The histidine residue predicted in the active site of UGT2B7 is invariant in
both human and plant enzymes (Figure 7C), while the stabilizing aspartic acid is invariant in
humans and the vast majority of plant enzymes. These data suggest that all human UGTs utilize
a similar catalytic mechanism of deprotonation by charge relay of an appropriate functional
group to carry out their promiscuous conjugative chemistry
Discussion
The high resolution crystal structure of the C-terminal domain of human UGT2B7 presented
here represents the first structural data on this class of phase II xenobiotic metabolizing
enzymes. Structural comparisons with related GT-B superfamily glycosyltransferases and
activity data from a panel of UGT2B7 point mutants revealed that human UGTs possess and
utilize a nucleotide-sugar binding site similar to those found in plant flavonoid
glucosyltransferases. Homology modeling of UGT2B7 further suggested that human UGTs
employ a serine hydrolase-like catalytic triad for catalysis, which was experimentally verified
with enzyme activity experiments using UGT2B7 mutated at critical catalytic residues
(His35, Asp151). In summary, our results provide a wealth of information about human UGT
function forming a framework from which the molecular mechanisms behind their donor-
substrate binding and catalytic activity can begin to be understood.
Human UGTs are promiscuous enzymes capable of conjugating glucuronic acid to a diverse
array of substrates. The predominant functional group used for conjugation is an –OH moiety,
although a number of additional functional groups, including sulfurs, amines and acidic
carbons, are also conjugated 2,34. This variability is apparently enabled by a serine hydrolase-
like catalytic triad, demonstrating the flexibility of this mechanism in human UGTs.
Unfortunately, this flexibility comes at the cost of efficiency, a hallmark of promiscuous
enzymes, as typical human UGT Kms are in the micromolar range.
The catalytic mechanism of related prokaryotic glycosyltransferases has been studied in some
detail. Structural analysis of these enzymes, in contrast to related human and plant enzymes,
did not reveal the presence of a His-Asp charge relay 16. Instead these enzymes require only
the presence of a general base in equivalent spatial space to deprotonate their acceptor
substrates, thus facilitating the sugar transfer. MurG has been shown to have a catalytic
histidine 30, while the Gtf family of enzymes was proposed to have two important catalytic
residues, a serine/threonine and an aspartic acid 21. Mutation of this aspartic acid residue in
GtfD to alanine abolished activity, while a similar alanine mutation of the threonine resulted
in attenuated activity 19. Replacement of the catalytic His35 in human UGT2B7 with an aspartic
acid, however, resulted in no activity (data not shown).
GT-B superfamily glycosyltransferase activity is divalent metal ion-independent; however,
divalent metal ions are required for some GT-B enzymes to achieve optimal activity 17,18. It
is clear from the structural data thus far accumulated that a divalent metal is not involved in
nucleotide-sugar binding, as it is in GTA superfamily glycosyltransferases. Enhancement of
activity by divalent metals could be occurring via interactions with acceptor substrates and
their subsequent N-terminal domain binding sites. Both phage T4 DNA β-glucosyltransferase
and MurG are activated by divalent metal ions, but structural data describing any kind of
acceptor substrate complex is lacking. Alternatively, it has been suggested that these metals
could be playing a role in product release 27. Our activity experiments with UGT2B7 in the
absence and presence of EDTA did not show any gain or loss of activity, suggesting divalent
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metals do not play a role with the acceptor substrates tested. Preliminary activity experiments
with other insect cell produced human UGTs and liver microsomes, however, suggest that the
activity of some UGTs are significantly enhanced by divalent metals (data not shown).
UGT2B7 is one of the predominant drug metabolizing UGTs in human tissues. A variety of
important drugs, including the anti-cancer drug epirubicin and the opioid-based pain medicines,
are inactivated via UGT2B7-mediated glucuronidation. A UGT inhibitor co-administered with
these drugs may allow for smaller doses of such drugs to be administered to patients, resulting
in higher efficacy and fewer side effects. The most similar region among all human UGTs is
the C-terminal nucleotide-sugar binding site. Some of the most effective UGT inhibitors, which
are based on a uridine/UDP moiety scaffold, exploit this characteristic 35. Unfortunately, these
inhibitors are likely to have serious side effects, as a number of critical biological processes
utilize nucleotide-sugars. Our structural data in conjunction with other GT1 family enzyme
structures may facilitate the development of additional scaffolds that are more UGT specific.
As additional structural information becomes available, the development of isoform-specific
UGT inhibitors may lead to safer, more effective co-therapies for a variety of conditions.
Materials and Methods
Protein Expression and Purification
Residues 285-451, which correspond to the C-terminal ER luminal domain, from of human
UGT2B7 cDNA (a generous gift from Dr. Peter Mackenzie, Flinders University, Australia)
were cloned into a pET based expression vector using ligation independent cloning techniques
36. This protein was expressed as a six-histidine tagged N-terminal maltose binding protein
(MBP) fusion protein via a linker containing a TEV protease site (HIS-MBP-TEV-2B7CT).
Protein expression was carried out in the methionine auxotroph E. coli strain B834 (DE3)
(Novagen) in SelenoMet media mix (Molecular Dimensions) containing 50 mg/L of
selinomethionine according to included protocols. E. coli cells were grown at 37° C to an
OD600 of 0.6. The temperature was lowered to 18° C and 0.1 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) added to induce protein expression. Ten hours post-induction
the cells were collected by centrifugation and resuspended into a lysis buffer containing 50
mM NaH2PO4 pH 8.0, 300 mM NaCl, 0.2% Triton X-100, 25 mM imidazole, and 0.01% Na
Azide. The cells were disrupted by sonication and centrifuged at 40,000g for 1hr at 4° C. The
resulting supernatant was subjected to affinity chromatography with Ni-6 sepherose media
(Amersham Biosciences). Purified fusion protein was eluted with an imidazole gradient and
the appropriate fractions pooled. Protein was diluted to 5 mg/ml or less, TEV protease added,
and the resulting solution dialyzed against cell lysis buffer minus Triton X-100 for 12 hrs at
room temp. Ni-6 sepherose affinity chromatography was used to remove uncleaved fusion and
MBP away from free 2B7CT, which was then concentrated and subjected to gel filtration
chromatography using a superdex75 column (Amersham Biosciences) equilibrated with 20
mM Hepes pH 7.4, 150 mM NaCl, and 0.01% Na Azide. Appropriate fractions were pooled,
dialyzed into a crystallization buffer (100 mM Ammonium Acetate pH 6.88, 75 mM NaCl,
0.01% Na Azide) and concentrated to 7 mg/ml.
To generate protein for UGT activity assays, full length human UGT2B7 (residues 1-529) was
cloned into a modified pFastBac DUAL vector (A generous gift from Dr. Daved H. Fremont,
Washington University St. Louis, MO) under the control of the polyhedron promoter as a C-
terminal enterokinase cleavable sixhistidine tag fusion. The vector modification entails the
replacement of the P10 promoter with the pBasic promoter which is used to drive the early
(18-24 hours) expression of eGFP, a visual marker for viral titering and infection. UGT2B7
point mutations were generated using site-directed mutagenesis. Recombinant bacmids and
virus were generated using the Bac-to-Bac system (Invitrogen) according to manufacturer's
protocols. Briefly, recombinant vector is transformed into the E. coli strain DH10BAC and
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recombination positive colonies are used to prepare recombinant bacmid, which is then
transfected into Sf9 insect cells growing in adherent culture using cellfectin. 72 hours post-
transfection, the virus containing medium is harvested and subjected to multiple rounds of
amplification with a multiplicity of infection (MOI) of 0.1. Full length protein was expressed
by infecting HighFive cells at a density of 1.5 × 106 per ml with recombinant virus at an MOI
of 5-10. 72 hours post-infection, cells are isolated by centrifugation, flash frozen in liquid
nitrogen and stored at −80° C. Microsomal fractions suitable for enzymatic activity assays were
prepared as described 37. The microsomes were resuspended in a solution containing 100 mM
potassium phosphate pH 7.4, 20% (v/v) glycerol, 0.1 mM EDTA, and 1 mM DTT to a
concentration of 10 mg/ml. The resulting samples were normalized with respect to UGT2B7
protein amounts using a combination of BCA assay and an anti-six-histidine western blot.
Crystallization
Initial crystallization conditions were generated from the free screening services offered by the
high throughput crystallization lab at the Hauptman-Woodward Institute (Buffalo, NY).
Several rounds of iterative refinement were carried out to adapt these initial crystallization hits
to hanging drop vapor diffusion methodology. Diffraction quality crystals of 2B7CT were
produced by mixing 1 μl of 7 mg/ml protein solution with 1 μl of reservoir solution (12-16%
PEG 4000, 100 mM K2CO3, 100 mM Tris pH 7.4) and equilibrating against 500 μl of reservoir
solution at 22° C. Crystals appeared within 1 week and grew as large hexagonal rods. Crystals
were cryoprotected by addition of 2 μl of well solution plus 20% ethylene glycol to the drop.
Crystals were immediately looped and flash-frozen in a 100° K nitrogen stream.
Structure determination
A three-wavelength (peak, inflection point, and high remote of the Se K-edge) SeMet MAD
experiment was carried out on beamline ID-22 (SER-CAT) at the Advanced Photon Source at
Argonne National Laboratory in Chicago, IL. An additional low-remote wavelength data
collection was conducted on a different part of the same crystal. Data were integrated, scaled
and reduced using HKL2000 38. SOLVE was used to find the positions of the Se atoms and
provide initial phase estimates 39. The resulting experimental electron density map was solvent
flattened and traced in an automated fashion using RESOLVE, generating a nearly complete
poly-alanine model 40,41. Additional tracing was carried out using COOT and the resulting
model refined with CNS using maximum likelihood targets 42,43. Final rounds of model
building and refinement were carried out using the high-resolution low-remote data set. A
summary of data collection, phasing, and refinement statistics can be found in Table 1.
Alternate conformations were observed and built for a number of amino acid side chains.
Molecular graphics for figures were generated with Pymol 44.
Enzymatic assays
Glucuronidation of androsterone, hyodeoxycholic Acid (HDCA) and tetrachlorocatechol
(TCC) (all from Sigma) were measured using protocols based on previously published
procedures 45. Briefly, membrane protein (10 μg) was incubated in 100 μM Tris-HCl (pH 7.4)/
5 mM MgCl2/5 mM saccharolactone/2% DMSO with each of the substrates (200 μM), in a
total volume of 30 μl. The reactions were started by the addition of [14C]UDPGA (4 mM) and
incubated at 37°C for 20 min. The reaction was stopped by addition of 30 μl of ethanol.
Aliquots (40 μl) of each sample were then applied to the preabsorbent layer of channeled silica
gel TLC plates (Baker 250Si-PA (19C); VWR Scientific, Sugarland, TX) and glucuronidated
products and unreacted substrate were separated by development in chloroform-methanol-
glacial acetic acid-water (65:25:2:4, v/v), with the exception of TCC, which was developed in
butanol-acetone-glacial acetic acid-30% ammonia-water (70:50:18:1.5:60). Radioactive
compounds were then localized on the TLC plates by autoradiography for 3-4 days at −80°C.
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Silica gel in areas corresponding to the glucuronide bands identified from autoradiograms and
corresponding areas from control lanes were scraped from the TLC plate into scintillation vials,
and the radioactivity was measured by liquid scintillation counting (Packard TRI-CARB
2100TR, Perkin-Elmer).
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Figure 1. Overall Structure of 2B7CT
(A) Asymmetric dimer present in the crystallographic asymmetric unit. (B) Solvent flattened
2.1 Å experimental electron density map contoured at 2σ. (C) Ribbon cartoon of 2B7CT with
labeled secondary structure elements.
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Figure 2. Comparison of C-terminal domains of GT1 family enzymes
Stereo image of the plant glucosyltransferase VvGT1 and bacterial GT GtfA C-terminal
domains superimposed to the 2B7CT structure.
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Figure 3. Sequence alignment of GT1 family enzymes
All unique C-terminal domain sequences from human UGTs were aligned to 2B7CT and the
conservation highlighted. This conservation mapping was extended to the structure based
sequence alignments of representative GT1 family GTs from both bacteria and plants if they
shared identity with human sequences. The secondary structure of 2B7CT is depicted above
its sequence and in gray above VvGT1 is secondary structure that is present in VvGT1 but
missing in 2B7CT. A shaded box is drawn around the regions that are important for donor
ligand binding. *-all UGT1A family members share an identical C-terminal domain.
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Figure 4. UGT2B7 has a nucleotide-sugar binding site most similar to plant flavonoid
glucosyltransferases (stereo pairs)
(A) Presumed UDPGA binding site of UGT2B7. Superposition of 2B7CT with the (B) plant
glucosyltransferase VvGT1 in complex with UDP-2-deoxy-2-fluro glucose and with (C) the
bacterial GT GtfA in complex with dTDP. Only residues that differ with 2B7CT are labeled.
(D) 2B7CT asymmetric dimer interface. C-terminus of Chain A (green and residues labeled)
packs into the UDPGA binding site of chain A (Yellow). UDP-2-deoxy-2-fluro glucose from
the superimposed VvGT1 is shown as a transparent object. *-denotes residues where multiple
conformations were observed.
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Figure 5. UDPGA binding site is highly conserved in humans
Human UGT sequence conservation (described in Figure 3) is mapped to the molecular surface
of 2B7CT. Yellow is invariant, magenta is conserved, and white signifies low conservation.
Using the VvGT1 structure as a guide UDPGA was modeled into the 2B7CT structure and is
shown in a ball and stick representation.
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Figure 6. Mutational analysis of the UGT2B7 UDPGA site
Activity assays were carried out with three distinct acceptor ligands: androsterone,
hyodeoxycholic acid (HDCA) and tetrachlorocatechol (TCC). The activity of each mutant was
normalized to wildtype levels and the results graphed according to their predicted interactions
with UDPGA (A,B,D,E). (C) Wildtype UGT2B7 activity assay conducted in the presence/
absence of EDTA.
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Figure 7. UGT2B7 utilizes a serine-hydrolase like catalytic triad for catalysis
(A) The VvGT1 structure in complex with both donor and acceptor ligands. An enlarged
representation of the VvGT1 catalytic region (cyan) is shown superimposed to a homology
model of UGT2B7 (yellow). (B) Schematic of a proposed catalytic reaction mechanism for
human UGT2B7. (C) Sequence alignment of human and plant GTs in regions important for
catalysis.
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Table 1
Summary of Data Collection, Phasing and Refinement
Data Collection for UGT2B7 C-terminal Domain
Space Group P6522
Unit Cell [abc, Å; αβγ, °] a,b=75.1 c=218.2 α,γ=90 β=120
Data Set Low EnergyRemote Peak Inflection
High Energy
Remote
Wavelength [Å] 0.98089 0.97925 0.97942 0.97174
X-ray Source APS SER-CAT 22-ID





No. of Reflections [unique] 33813 25127 21866 25168
Completeness [%] 97.7 (94.3) 97.7 (96.9) 97.8 (97.1) 97.7 (97.0)
Rsym 
a [%] 5.6 (39.2) 9.8 (33.4) 10.0 (40.6) 8.7 (42.9)
I/σ 50 (6.5) 19.2 (6.9) 18.0 (6.0) 22.1 (5.9)
Redundancy 14.4 (13.4) 10.6 (11.0) 10.7 (11.1) 10.8 (11.1)
MAD Phasing Statistics out to 2.1 Å
Se atom sites in AU (observed/total) 12/14
Mean Figure of Merit
    Solve (Highest shell) 0.63 (0.41)
    Resolve (Highest shell) 0.71 (0.60)
Refinement Summary
Resolution [Å] (Highest shell) 50−1.80 (1.91−1.8)
Molecules per asymmetric unit (AU) 2
No. of protein atoms/AU 2673
No. of waters/AU 283
Rworking 
b [%] 21.9 (29.6)
Rfree 
c [%] 24.5 (34.9)










    most, allowed, generous, disallowed 95.3, 3.9 ,0.7, 0.0
PDB ID code 2O6L
a
Rsym = Σ|I− I |/ Σ|I|, where I is the observed intensity and <I> is the average intensity of several symmetry-related observations.
b
Rworking = Σ||Fo|−|Fc||/ Σ|Fo, where Fo and Fc are the observed and calculated structure factors, respectively.
c
Rfree = Σ||Fo|−|Fc||/ Σ|Fo for 5% of the data not used at any stage of the structural refinement; 5% data omitted for Rfree
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